Skip to main content
♕ The Globe and Mail Trade Off
Canada's free stock market contest is live! Test your investing skills for a chance to win $5,000.Enter Now!Enter Now!
➜

Moderna Inc(MRNA-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low49.22
Day High52.77
Open:52.22
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

TOP STORIES: Moderna Inc

Select a category then submit the form to load news
StockStory
PacBio, CONMED, Moderna, QuidelOrtho, and Tandem Diabetes Shares Are Falling, What You Need To Know
PACB
Tipranks
Moderna Reaches Major Patent Settlement on mRNA Vaccines
Stock Target Advisor
Oil Price Surge Sinks Stocks-Market Analysis for March 5th, 2026
Oil Price Surge Sinks Stocks-Market Analysis: March 5th, 2026
Tipranks
Moderna (MRNA) Receives a Hold from Evercore ISI
Tipranks
Analysts Offer Insights on Healthcare Companies: Quantum-Si (QSI), Moderna (MRNA) and Nuvalent (NUVL)
StockStory
Why Moderna (MRNA) Stock Is Trading Up Today
MRNA
Motley Fool
2 High-Flying Stocks With More Upside to Buy and Hold
Tipranks
Analysts Are Bullish on These Healthcare Stocks: Nyxoah (NYXH), Moderna (MRNA)
Zacks Investment Research
MRNA Stock Gains After CHMP Endorses COVID-19-Influenza Combo Shot
MRNA Stock Gains After CHMP Endorses COVID-19-Influenza Combo Shot
Tipranks
Wall Street Analysts Are Neutral on Top Healthcare Picks
Motley Fool
Moderna's Ups and Downs: Here's What You Need to Know Before Investing.
StockStory
3 Reasons to Avoid MRNA and 1 Stock to Buy Instead
MRNA
Stock Target Advisor
Tariff Confusion Sinks Stocks: Market Analysis for Februrary 23rd, 2026
Tariff Confusion Sinks Stocks: Market Analysis for Februrary 23rd, 2026
GlobeNewswire
Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board
Motley Fool
Here's Why I Wouldn't Touch Moderna With a 10‑Foot Pole Until Its Next Growth Engine Is Clear
Tipranks
Moderna Faces Default Risk as Ares Capital–Led Lenders Gain Power to Accelerate Debt and Seize Collateral
Tipranks
Moderna and Merck Advance mRNA Cancer Vaccine Trial in First-Line Lung Cancer: What Investors Should Watch
Motley Fool
Billionaire Philippe Laffont Just Dumped CoreWeave and Opened a Position in a Stock That Soared Nearly 50% in January.
StockStory
Moderna’s Q4 Earnings Call: Our Top 5 Analyst Questions
MRNA
Tipranks
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Moderna (MRNA) and NewAmsterdam Pharma Company (NAMS)
Tipranks
Analysts Offer Insights on Healthcare Companies: Moderna (MRNA) and Alnylam Pharma (ALNY)
Zacks Investment Research
Moderna Stock Jumps After FDA Reverses Course on Flu Shot
Moderna Stock Jumps After FDA Reverses Course on Flu Shot
Tipranks
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF), Incyte (INCY) and Moderna (MRNA)
Motley Fool
3 Once-in-a-Decade Buying Opportunities
Motley Fool
Stock Market Today, Feb. 18: Nvidia Rallies As Meta Deal Boosts AI Confidence
StockStory
Why Moderna (MRNA) Stock Is Trading Up Today
MRNA
Motley Fool
Why Moderna Stock Just Popped
Tipranks
Analysts Conflicted on These Healthcare Names: Ansell (OtherANSLF), Moderna (MRNA) and Humana (HUM)
StockStory
3 Stocks Under $50 with Warning Signs
MTCH
Tipranks
RBC Capital Remains a Hold on Moderna (MRNA)
Motley Fool
Shopify's Whiplash Day
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Crispr Therapeutics AG (CRSP), Moderna (MRNA) and Disc Medicine (IRON)

Profile

Moderna, Inc. is a clinical-stage pharmaceutical company, primarily focused on discovering and developing messenger RNA (mRNA) based therapies. The company's mRNA based COVID-19 vaccine, Spikevax (mRNA-1273), is approved for use in adults in the United States. The vaccine is also authorized for emergency use in several countries as COVID-19 vaccine. The company has also developed booster doses of its COVID-19 vaccine and is developing variant-specific booster candidates.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.